Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Disease
- Therapeutic
- Drug Discovery
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 253935
For the technology Transfer by Licensor, Licensor grants to Licensee the exclusive, even as to Licensor and its Affiliates, license, non-transferable, with the right to sublicense, under the Licensor Patents and Licensor Know-How, to make, have made, use, sell, offer to sell, export, import and otherwise exploit or Commercialize Licensed Products that are the subject of the Option so exercised, during the Term, and throughout the Field and the Territory.
5-HT4 Partial Agonist Program means EPIXs program to develop a partial agonist to the 5-HT4 receptor.
Licensor Program means a program of drug design, discovery and Development activities to be conducted by Licensor hereunder against Program Targets. The first Licensor Program is the 5-HT4 Partial Agonist Program.
The patents are for Thienopyridinone Compounds and Methods of Treatment.
GPCRs are the largest known class of molecular targets with proven therapeutic value. Of the top 50 selling drug worldwide, as identified by IMS, it is estimated that nearly 40 percent interact with GPCRs as their target proteins. GPCRs convert signals received from outside the cell into biological processes inside the cell.
The strategic collaboration agreement is to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX’s novel 5-HT4 partial agonist program, PRX-03140, in early-stage clinical development for the treatment of Alzheimer’s disease.
IPSCIO Record ID: 369410
Licensor shall be hereby deemed to have granted and hereby grants to Licensee the exclusive right and license, even as to Licensor and its Affiliates, except for the limited purpose of conducting Research and Development activities with respect to Back-up Compounds or formulations in the Territory, with the right to grant sublicenses, right, title and interest in and to the Exclusively Licensed lP to make, have made, use, sell, offer for sale and import Compounds under such Licensor Program as and into Licensee Products in the Field during the Term.
For the Technology Transfer after Option Exercise, Licensor shall deliver to Licensee, all Information and material in its possession and Control relating to the Compounds, in such Licensee Development Program, and any other such Information as may be in Licensors Control and in the possession of any subcontractors appointed by Licensor.
This strategic alliance is to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.
Compound means each compound comprising an oligonucleotide-based immunoregulatory sequence (IRS) that inhibits IC50 < 200nM in a cellular assay.
The Field means any use or purpose, including without limitation, the treatment, palliation, prevention and/or diagnosis of any human or animal disease, disorder or condition, whether as a prescription pharmaceutical product or over-the-counter medicine or otherwise.
This agreement will carry out up to three different research and development programs to discover and develop oligonucleotides as inhibitors of certain toll-like receptors or combinations thereof.
IPSCIO Record ID: 203240
For commercialization, Licensor grants to the Licensee of England, the exclusive, right and license in the Territory, with the right to grant sublicenses, under all of Licensors rights, title and interest in and to the Licensors Technology, to make, have made, use, sell, offer for sale and import the Progressed Compounds which are the subject of each of such Product Options as and into Product Candidates and as and into Licensed Products in the Field during the Term of this Agreement.
For Trademarks for licensed Products, Licensor shall assign its rights and title to such trademark(s) to Licensee, upon request.
Licensor grants the exclusive right, exercisable at Licensees sole discretion, to elect to obtain exclusive worldwide rights to continue to develop and commercialize at least four (4) and no more than six (6) Option Compounds (and their associated Back-up Compounds), as Product Candidates and into Licensed Products.
The patents include Sulfonamides, Piperazines and derivatives for inflammation and immunes.
Traficet-EN is intended to control the inflammatory response underlying inflammatory bowel disease, or IBD, by targeting the chemokine receptor known as CCR9. In adults, CCR9 is found primarily on a population of T cells, a subset of the body’s inflammatory cells, that migrate selectively to the digestive tract.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of RA patients contains high levels of activated CCR1 chemokine ligands. Blocking CCR1 is intended to reduce inflammation and prevent subsequent joint destruction by suppressing the infiltration of inflammatory cells into the arthritic joint.
Traficet-EN (CCX282 or GSK’786) — Our most advanced drug candidate, currently in three pivotal Phase III clinical trials being conducted by our partner for the treatment of patients with moderate-to-severe Crohn’s disease.
Field shall mean any use or purpose, including without limitation the treatment, palliation, and/or prevention of any human or animal disease, disorder or condition; provided, however, that the Field shall specifically exclude the commercialization of protein therapeutics directed against Collaboration Targets.
IPSCIO Record ID: 203410
Licensor grants the Japanese Licensee an exclusive, except as to Licensor, license, with the right to sublicense, under the Program Patents, Program Know-How and the Licensor Technology to the extent necessary or useful to develop, have developed, make, have made, use, import, offer for sale, sell and have sold any Product in the CoCommercialization Territory; and an exclusive even as to Licensor, license, with the right to sublicense, under the Program Patents, Program Know-How and the Licensor Technology to develop, have developed, make, have made, use, import, offer for sale, sell and have sold any Product in the Licensrr Territory.
Licensor grants, to the extent Licensee is developing a Licensee Lead Compound or developing or commercializing a Licensee Product, an exclusive even as to Licensor, worldwide license, with the right to sublicense, under Licensors interest in the Program Patents and Program Know-How; and a non-exclusive, worldwide license, with the right to sublicense, under the Licensor Technology, in each case to develop or have developed Licensee Lead Compounds and to develop, have developed, make, have made, use, import, offer for sale, sell and have sold Licensee Products incorporating a Licensee Lead Compound.
Such Lead Compound or Research Compound shall be designated a Collaboration Lead Compound and any products incorporating or based upon such Collaboration Lead Compound for which an IND is submitted to a regulatory authority shall be designated as a Product.
Program shall mean the collaborative program under which Licensor and Licensee will conduct the Research Program and discover, develop, manufacture and market Products with activity against the Collaboration Targets or the Current Program Targets in the Field.
G-protein coupled receptors (GPCRs) are proteins that traverse the cell membrane seven times (also referred to as heptahelical receptors). These proteins regulate diverse biological functions including sight, taste and smell. Furthermore, GPCRs are involved in the regulation of inflammation, blood pressure, reproduction, digestion and appetite.
IPSCIO Record ID: 203480
The Parties are establishing a collaborative effort to perform research and develop and market products for the prevention, diagnosis, and treatment of skeletal muscle disorders.
For the Termination of the Multi-Project Collaboration Agreement and Overview and Management of Collaboration portion of this Collaboration agreement, the Multi-Project Collaboration Agreement is hereby terminated, and contrary to the Multi-Project Collaboration Agreement, Licensee shall own all Inventions discovered by employees of Licensee as part of any Licensee Retained Project and having no utility in the Field as of the Effective Date.
Licensor grants an exclusive License under its Patents and Know-how whether solely owned by Licensor or jointly owned with Licensee which were conceived and reduced to practice in connection with any Licensee Retained Project at any time through December 31, 2000 and as of December 31, 2000 have no known use in the Field or in any Licensor Retained Project to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any diseases or disorders in humans or animals in connection with any Licensee Retained Project.
Licensor grants a non-exclusive License under its Patents and Know-how which were conceived and reduced to practice in connection with any Licensee Retained Project at any time through December 31, 2000 and as of December 31, 2000 have known use in the Field or in any Licensor Retained Project, to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any disease or disorder in humans or animals in connection with any Licensee Retained Project.
Licensor grants a non-exclusive License under its Patents and Know-how conceived and reduced to practice in connection with any Mutual Retained Project at any time through December 31, 2000, to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any disease or disorder in humans or animals.
For the Scope of Collaboration, the Parties will work together to research, develop and commercialize Lead Compounds pursuant to this Agreement in the Territory.
Agrin means the compounds claimed in the United States Patent Application Serial Number 08/644,271 and any continuations, divisionals or continuation-in-parts thereof, and any molecules representing one or more amino acid substitutions, deletions, or additions derived therefrom.
Compound means a chemical entity, which is not Excluded Technology, with research or commercial utility in the Field for methods of research, diagnosis, treatment or prevention of any disease or disorder in humans or animals, and which is conceived and/or reduced to practice by Licensee, or acquired by Licensee from a Third Party with the right to sublicense, before or during the Research Term; or is conceived and/or reduced to practice by Licensor, or acquired by Licensor from a Third Party with the right to sublicense, prior to or during the Research Term.
GPCR means a G-protein coupled receptor.
Field means the collective areas in which the Parties shall collaborate encompassing the discovery, development, supply and commercialization of products or processes in the Muscle Field, the GPCR Field or the DDR Field.
DDR Field means the discovery, development, supply and commercialization of products or processes that modulate the function of the receptor tyrosine kinases DDR1 and/or DDR2 (or any receptor having at least seventy-five percent (75%) homology with DDR1 or DDR2) whose biological action is primarily due to this modulation.
GPCR Field means the discovery, development, supply and commercialization of products or processes that directly bind and/or modulate the function of the twelve GPCRs.
Muscle Field means the discovery, development, supply and/or commercialization of products (except MuSK and/or Agrin) or processes that diagnose, prevent and/or treat conditions in humans and animals associated with the promotion or protection of skeletal muscle mass or function (including, without limitation, the diagnosis, treatment or prevention of muscle atrophy or sarcopenia).
IPSCIO Record ID: 215176
In addition to the cross license, the Japanese Licensor will grant an exclusive, sub-licensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under Licensors interest in Program Patents and Program Know-How and under terms and conditions to be separately agreed, Licensor will also grant a nonexclusive, sub-licensable, worldwide license under any Licensor Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How, including, with respect to compounds, a limited number of Licensors library compounds approved by Licensor.
And Licensor grants an exclusive, except as to Licensor, license, with the right to sublicense under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor during the Term to the extent necessary to develop, make, have made, use, import, offer for sale and sell any Product in the Co-Promotion Territory; and an exclusive, even as to Licensor, license, with the right to sublicense, under the Program Patents, Program Know-How, Patent Rights and Know-How owned or controlled by Licensor during the Term to the extent necessary to develop, make, have made, use, import, offer for sale and sell, with the right to sublicense, any Product in the Licensees Territory.
An orphan receptor is an apparent receptor that has a similar structure to other identified receptors but whose endogenous ligand has not yet been identified. If a ligand for an orphan receptor is later discovered, the receptor is referred to as an 'adopted orphan'.
Orphan nuclear receptors act as regulatory proteins in a wide variety of biological processes. This, in combination with the fact that nuclear receptors are known to be activated by naturally occurring small molecules, makes orphan nuclear receptors excellent targets for orally active drugs. The goal of the collaboration is to clarify the biology of individual orphan nuclear receptors and to discover small molecules that are capable of regulating the activity of these receptors to cure or control disease.
Independent Products incorporate or are based on such Collaboration Lead Compound.
